ATHINA GOLIOPOULOU

Dr. ATHINA GOLIOPOULOU


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2023 in Molecules
Verified
Journal Article
Open access
PDF file
Stamatios LampsasStamatios Lampsas
Stamatios Lampsas
MXMaria Xenou
Maria Xenou
EVANGELOS OIKONOMOUEVANGELOS OIKONOMOU
EVANGELOS OIKONOMOU
Panteleimon PantelidisPanteleimon Pantelidis
Panteleimon Pantelidis
ALAntonios Lysandrou
Antonios Lysandrou
GSGerasimos Siasos
Gerasimos Siasos
Lipoprotein(a) (Lp(a)) is a low-density lipoprotein (LDL) cholesterol-like particle bound to apolipoprotein(a). Increased Lp(a) levels are an independent, heritable causal risk factor for atherosclerotic cardiovascular disease (ASCVD) as they are largely determined by variations in the Lp(a) gene (LPA) locus encoding apo(a). Lp(a) is the preferential lipoprotein carrier for oxidized phospholipids (OxPL), and its role adversely affects vascular inflammation, atherosclerotic lesions, endothelial function and thrombogenicity, which pathophysiologically leads to cardiovascular (CV) events. Despite this crucial role of Lp(a), its measurement lacks a globally unified method, and, between different laboratories, results need standardization. Standard antilipidemic therapies, such as statins, fibrates and ezetimibe, have a mediocre effect on Lp(a) levels, although it is not yet clear whether such treatments can affect CV events and prognosis. This narrative review aims to summarize knowledge regarding the mechanisms mediating the effect of Lp(a) on inflammation, atherosclerosis and thrombosis and discuss current diagnostic and therapeutic potentials.

Verified
Journal Article
Open access
PDF file
AGATHINA GOLIOPOULOU
ATHINA GOLIOPOULOU
PTPanagiotis Theofilis
Panagiotis Theofilis
EVANGELOS OIKONOMOUEVANGELOS OIKONOMOU
EVANGELOS OIKONOMOU
AAArtemis Anastasiou
Artemis Anastasiou
Panteleimon PantelidisPanteleimon Pantelidis
Panteleimon Pantelidis
GSGerasimos Siasos
Gerasimos Siasos
The cardiovascular implications of non-alcoholic fatty liver disease (NAFLD) have been associated with heart failure with preserved ejection fraction (HFpEF). The purpose of this review was to conduct a bibliographic search regarding the correlation between NAFLD and the echocardiographic parameters of left ventricular diastolic function. A systematic literature search was conducted in PubMed and Embase for original research data reporting on the association of NAFLD with diastolic function markers [E/e′, left atrial volume index (LAVi), left ventricular mass index (LVMi)]. Meta-analysis was performed using the meta and dmetar packages in R studio v.1.4.1106, with p < 0.05 values being considered significant. Results are expressed as the standardized mean difference (SMD) for continuous variables and as the odds ratio (OR) for categorical variables, with respective 95% confidence intervals (CI). Heterogeneity between studies was expressed with index Ι2. From the preliminary search, 2619 articles were found from which 31 studies were included in the final statistical analysis. The meta-analysis of 8 studies which reported on the prevalence of diastolic dysfunction showed that it was increased in patients with NAFLD (OR: 2.07, 95% CI 1.24–3.44 with p = 0.01, I2: 80% with p < 0.01). The meta-analysis of 21 studies showed significantly higher E/e′ in NAFLD patients (SMD 1.02, 95% CI 0.43–1.61 with p < 0.001, I2: 97% with p < 0.001). Individuals with NAFLD had increased LAVi (SMD: 0.87, 95% CI 0.38–1.37 with p < 0.001, I2: 96% with p < 0.001) and LVMi (SMD: 0.89, 95% CI 0.31–1.48 with p = 0.003, I2: 100% with p < 0.001). To conclude, in the meta-analysis of 31 observational studies, NAFLD patients were found to have affected left ventricular diastolic function, supporting the hypothesis of NAFLD being associated with HFpEF.

23 April 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
Panteleimon PantelidisPanteleimon Pantelidis
Panteleimon Pantelidis
Polychronis DilaverisPolychronis Dilaveris
Polychronis Dilaveris
SRSamuel Ruipérez-Campillo
Samuel Ruipérez-Campillo
AGATHINA GOLIOPOULOU
ATHINA GOLIOPOULOU
AGAlexios Giannakodimos
Alexios Giannakodimos
GSGerasimos Siasos
Gerasimos Siasos
Artificial intelligence (AI) is transforming cardiovascular medicine by enabling the analysis of high-dimensional biomedical data with unprecedented precision. Initially employed to automate human tasks such as electrocardiogram (ECG) interpretation and imaging segmentation, AI’s true potential lies in uncovering hidden disease data patterns, predicting long-term cardiovascular risk, and personalizing treatments. Unlike human cognition, which excels in certain tasks but is limited by memory and processing constraints, AI integrates multimodal data sources—including ECG, echocardiography, cardiac magnetic resonance (CMR) imaging, genomics, and wearable sensor data—to generate novel clinical insights. AI models have demonstrated remarkable success in early dis-ease detection, such as predicting heart failure from standard ECGs before symptom on-set, distinguishing genetic cardiomyopathies, and forecasting arrhythmic events. However, several challenges persist, including AI’s lack of contextual understanding in most of these tasks, its “black-box” nature, and biases in training datasets that may contribute to disparities in healthcare delivery. Ethical considerations and regulatory frameworks are evolving, with governing bodies establishing guidelines for AI-driven medical applications. To fully harness the potential of AI, interdisciplinary collaboration among clinicians, data scientists, and engineers is essential, alongside open science initiatives to promote data accessibility and reproducibility. Future AI models must go beyond task automation, focusing instead on augmenting human expertise to enable proactive, precision-driven cardiovascular care. By embracing AI’s computational strengths while addressing its limitations, cardiology is poised to enter an era of transformative innovation beyond traditional diagnostic and therapeutic paradigms.

23 September 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
VLVaia Lambadiari
Vaia Lambadiari
EMMANOUIL KORAKASEMMANOUIL KORAKAS
EMMANOUIL KORAKAS
EVANGELOS OIKONOMOUEVANGELOS OIKONOMOU
EVANGELOS OIKONOMOU
EBEvanthia Bletsa
Evanthia Bletsa
AKAIKATERINI KOUNTOURI
AIKATERINI KOUNTOURI
GSGerasimos Siasos
Gerasimos Siasos
Capillary leak syndrome is an under-diagnosed condition leading to serious hypoalbuminemia with diffuse edema, pulmonary edema, severe hypotension, and possibly death. Sepsis leading to hemophagocytic lymphohistiocytosis (HLH) is a major risk factor; however, capillary hyper-permeability is the core underlying pathophysiological mechanism. Endothelial dysfunction plays a major role in cardiometabolic disease through insulin resistance, lipotoxicity, and, eventually, oxidative stress and chronic inflammation. We review the literature concerning the aforementioned mechanisms as well-established risk factors for adverse COVID-19 outcomes. We especially focus on data regarding the underlying endothelial effects of SARS-CoV-2 infection, including direct damage and increased vascular leakage through a hyper-inflammatory cascade and diminished nitric oxide bioavailability. Interestingly, an increased incidence of hypoalbuminemia has been observed in patients with severe COVID-19, especially those with underlying cardiometabolic disease. Importantly, low albumin levels present a strong, positive association with poor disease outcomes. Therefore, in this review article, we highlight the important role of cardiovascular risk factors on endothelium integrity and the possible link of endothelial damage in the hypoalbuminemia-associated adverse prognosis of COVID-19 patients.

3 May 2022 in Angiology
Verified
Journal Article
Closed access
AGATHINA GOLIOPOULOU
ATHINA GOLIOPOULOU
EVANGELOS OIKONOMOUEVANGELOS OIKONOMOU
EVANGELOS OIKONOMOU
AAAlexis Antonopoulos
Alexis Antonopoulos
NKNikolaos Koumallos
Nikolaos Koumallos
MGMaria Gazouli
Maria Gazouli
DTDimitris Tousoulis
Dimitris Tousoulis
Little is known about the role of serum and tissue mediators in the progression of ascending aortic aneurysms and dissections. We examined how the tissue expression of microRNAs and matrix metalloproteinases (MMPs), as well as the serum levels of osteoprotegerin, adiponectin, and high sensitivity C-reactive protein (hsCRP) are associated with these entities. We enrolled 21 patients with ascending aortic aneurysm, 11 with acute Stanford type A aortic dissection and 18 controls. The serum levels of osteoprotegerin, adiponectin, and hsCRP, as well as the tissue expression of MMPs 2 and 9 and tissue microRNAs 29 and 195 were compared among groups. There was no difference regarding serum osteoprotegerin, adiponectin, and tissue MMP2 and MMP9 levels. hsCRP was higher in the dissection group ( P = .03). Tissue expression of microRNA 29 was 2.11-fold higher in the dissection ( P = .001) and 2.99-fold higher in the aneurysm group ( P < .001), compared with the control group. Tissue expression of microRNA 195 was 2.72-fold higher in the dissection ( P < .001) and 2.00-fold lower in the aneurysm group ( P = .08), compared with to the control group. These findings support the contribution of microRNAs in the progression of aneurysm formation and dissection, suggesting a role as potential biomarkers and future therapeutic targets.

Verified
Journal Article
Open access
PDF file
George E. ZakynthinosGeorge E. Zakynthinos
George E. Zakynthinos
IGIoannis Gialamas
Ioannis Gialamas
VTVASILIKI TSOLAKI
VASILIKI TSOLAKI
Panteleimon PantelidisPanteleimon Pantelidis
Panteleimon Pantelidis
AGATHINA GOLIOPOULOU
ATHINA GOLIOPOULOU
EVANGELOS OIKONOMOUEVANGELOS OIKONOMOU
EVANGELOS OIKONOMOU
Hypertrophic cardiomyopathy (HCM) is a complex and heterogeneous cardiac disorder, often complicated by cardiogenic shock, a life-threatening condition marked by severe cardiac output failure. Managing cardiogenic shock in HCM patients presents unique challenges due to the distinct pathophysiology of the disease, which includes dynamic left ventricular outflow tract obstruction, diastolic dysfunction, and myocardial ischemia. This review discusses current and emerging therapeutic strategies tailored to address the complexities of HCM-associated cardiogenic shock and other diseases with similar pathophysiology that provoke left ventricular outflow tract obstruction. We explore the role of pharmacological interventions, including the use of vasopressors and inotropes, which are crucial in stabilizing hemodynamics but require careful selection to avoid exacerbating the outflow obstruction. Additionally, the review highlights advancements in mechanical circulatory support devices such as extracorporeal membrane oxygenation (ECMO) and left ventricular assist devices (LVADs), which have become vital in the acute management of cardiogenic shock. These devices provide temporary support and bridge patients to recovery, definitive therapy, or heart transplantation, which remains a critical option for those with end-stage disease. Furthermore, the review delves into the latest research and clinical trials that are refining these therapeutic approaches, ensuring they are optimized for HCM patients. The impact of these treatments on patient outcomes, including survival rates and quality of life, is also critically assessed. In conclusion, this review underscores the importance of a tailored therapeutic approach in managing cardiogenic shock in HCM patients, integrating pharmacological and mechanical support strategies to improve outcomes in this high-risk population.